Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin as Add-on to Metformin in Type 2 Diabetes
NCT01215097Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Oct 2010; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01215097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01215097.